Phathom Pharmaceuticals Inc (NAS:PHAT)
$ 10.61 -0.25 (-2.3%) Market Cap: 846.21 Mil Enterprise Value: 831.61 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 23/100

Q4 2025 Phathom Pharmaceuticals Inc Earnings Call Transcript

Feb 26, 2026 / 01:00 PM GMT
Release Date Price: $13.56 (+9.89%)

Key Points

Positve
  • Phathom Pharmaceuticals Inc (PHAT) reported a successful Q4, delivering on expectations for both revenue and cash operating expenses, coming in at the better end of their guided ranges.
  • The company achieved a 217% year-over-year growth in net revenues for the full year 2025, reaching $175.1 million.
  • Phathom Pharmaceuticals Inc (PHAT) has taken significant steps to enhance its capital structure, including reducing interest expenses and modifying outstanding term loan obligations.
  • The company is on track to achieve operating profitability by Q3 2026 and cash flow positivity in 2027.
  • Phathom Pharmaceuticals Inc (PHAT) has a nearly full-strength sales organization, with more than 285 of their 300 sales positions filled, and is seeing clear signs that their GI strategy is working.
Negative
  • The company faces typical seasonality challenges, with Q1 expected to be the weakest quarter due to winter storms and plan resets.
  • Phathom Pharmaceuticals Inc (PHAT) does not anticipate a fundamental change in broad Medicare coverage, which may limit access for some patients.
  • The company acknowledges that the majority of prescriptions come from prior patients, indicating a reliance on existing customers for growth.
  • There is a potential risk of increased competition in the PCA space, with other companies developing similar products.
  • Phathom Pharmaceuticals Inc (PHAT) has not yet made decisions on pursuing additional indications beyond EOE for their product, which may limit future growth opportunities.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PHAT.OQ - Phathom Pharmaceuticals Inc
Q4 2025 Phathom Pharmaceuticals Inc Earnings Call
Feb 26, 2026 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Hello and welcome to Fathom Pharmaceuticals 4th quarter and full year 2025 earnings results call. At this time, all participants are in the listen-only mode. After the presentation, there will be a question-and-answer session.

To ask a question, please press 11 on your telephone keypad. Please be advised that today's call is being recorded. With that, I would like to turn the call over to Eric Sciarrelli, Fathom's head of investor relations. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you operator. Hello everyone and thank you for
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot